Literature DB >> 18361945

Current therapies for pseudomonas aeruginosa.

Helen Giamarellou1, Kyriaki Kanellakopoulou.   

Abstract

Based on the worldwide prevalence of multidrug-resistant strains of Pseudomas aeruginosa and the fact that no newer antipseudomonal agents are available, this article aims to investigate therapeutic solutions for combating infections caused by P aeruginosa, including multidrug-resistant strains. The article focuses mainly on colistin, the re-emerging old antibiotic that possesses prominent antipseudomonal activity in vitro and on doripenem, a newer carbapenem that seems to be close to its global marketing. Regarding older antipseudomonal antibiotics that have been reviewed extensively, only newer aspects on their use are considered in this article.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18361945     DOI： 10.1016/j.ccc.2007.12.004

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN： 0749-0704            Impact factor:   3.598


  18 in total

1.  Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates?

Authors:  Maria Souli; Panagiota Danai Rekatsina; Zoi Chryssouli; Irene Galani; Helen Giamarellou; Kyriaki Kanellakopoulou
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

2.  Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.

Authors:  Carolina Alvarez-Ortega; Irith Wiegand; Jorge Olivares; Robert E W Hancock; José Luis Martínez
Journal:  Antimicrob Agents Chemother       Date:  2010-08-02       Impact factor: 5.191

3.  Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa.

Authors:  Seungil Han; Richard P Zaniewski; Eric S Marr; Brian M Lacey; Andrew P Tomaras; Artem Evdokimov; J Richard Miller; Veerabahu Shanmugasundaram
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-06       Impact factor: 11.205

4.  Diphosphonium ionic liquids as broad-spectrum antimicrobial agents.

Authors:  George A O'Toole; Michel Wathier; Michael E Zegans; Robert M Q Shanks; Regis Kowalski; Mark W Grinstaff
Journal:  Cornea       Date:  2012-07       Impact factor: 2.651

5.  Role of Pseudomonas aeruginosa AmpR on β-lactam and non-β-lactam transient cross-resistance upon pre-exposure to subinhibitory concentrations of antibiotics.

Authors:  Hansi Kumari; Deepak Balasubramanian; Diansy Zincke; Kalai Mathee
Journal:  J Med Microbiol       Date:  2014-01-25       Impact factor: 2.472

6.  Small molecule screen yields inhibitors of Pseudomonas homoserine lactone-induced host responses.

Authors:  Cathleen D Valentine; Hua Zhang; Puay-Wah Phuan; Juliane Nguyen; A S Verkman; Peter M Haggie
Journal:  Cell Microbiol       Date:  2013-08-22       Impact factor: 3.715

7.  Identification and Characterization of Chemical Compounds that Inhibit Leucyl-tRNA Synthetase from Pseudomonas aeruginosa.

Authors:  Regina Zamacona; Pamela N Chavero; Eduardo Medellin; Yanmei Hu; Casey A Hughes; Nathalie Quach; Megan Keniry; James M Bullard
Journal:  Curr Drug Discov Technol       Date:  2020

Review 8.  Doripenem: a review of its use in the treatment of bacterial infections.

Authors:  Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 9.  Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa in an endemic area: comparison with global data.

Authors:  Theodoros Karampatakis; Charalampos Antachopoulos; Athanassios Tsakris; Emmanuel Roilides
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-04-11       Impact factor: 3.267

10.  Characterization and structure determination of prolyl-tRNA synthetase from Pseudomonas aeruginosa and development as a screening platform.

Authors:  Noah Pena; David M Dranow; Yanmei Hu; Yaritza Escamilla; James M Bullard
Journal:  Protein Sci       Date:  2019-02-06       Impact factor: 6.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.